Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran.
Silvia CalabriaEmanuele ForcesiLetizia DondiAntonella PedriniAldo Pietro MaggioniNello MartiniPublished in: Cardiovascular drugs and therapy (2018)
This analysis of the ARCO database reliably describes the population potentially eligible to the dabigatran reversal agent, idarucizumab. These data may be useful for Healthcare Decision Makers to organize, define, and improve present and future emergency healthcare, mainly as starting point for cost-effectiveness analyses of new reversal agents.
Keyphrases
- healthcare
- atrial fibrillation
- minimally invasive
- emergency department
- public health
- coronary artery bypass
- electronic health record
- big data
- coronary artery disease
- acute coronary syndrome
- decision making
- drug induced
- health information
- percutaneous coronary intervention
- social media
- data analysis
- emergency medical